Immune infiltrates as predictive markers of survival in pancreatic cancer patients

Frontiers in Physiology

Volumn 4 AUG, Issue , 2013, Pages

  Protti, Maria Pia ^a   De Monte, Lucia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Macrophages; Mast cells; Pancreatic cancer; Survival predictive factor; Tumor infiltrating lymphocytes; Univariate and multivariate analyses

Indexed keywords

CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE FREE SURVIVAL; HUMAN; MACROPHAGE; MAST CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; SHORT SURVEY; SURVIVAL PREDICTION; TH1 CELL; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84884583506     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2013.00210     Document Type: Short Survey

References (56)

1. Ademmer, K., Ebert, M., Muller-Ostermeyer, F., Friess, H., Buchler, M. W., Schubert, W., et al. (1998). Effector T lymphocyte subsets in human pancreatic cancer: detection of CD8+CD18+ cells and CD8+CD103+ cells by multi-epitope imaging. Clin. Exp. Immunol. 112, 21-26. doi: 10.1046/j.1365-2249.1998.00546.x
2. Balkwill, F. R., and Mantovani, A. (2012). Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 22, 33-40. doi: 10.1016/j.semcancer.2011.12.005
3. Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., et al. (2011). CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616. doi: 10.1126/science.1198443
4. Cai, S. W., Yang, S. Z., Gao, J., Pan, K., Chen, J. Y., Wang, Y. L., et al. (2011). Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. Surgery 149, 576-584. doi: 10.1016/j.surg.2010.10.009
5. Chang, D. Z., Ma, Y., Ji, B., Wang, H., Deng, D., Liu, Y., et al. (2011). Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 17, 7015-7023. doi: 10.1158/1078-0432.CCR-11-0607
6. Clark, C. E., Beatty, G. L., and Vonderheide, R. H. (2009). Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett. 279, 1-7. doi: 10.1016/j.canlet.2008.09.037
7. De Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H., et al. (2011). Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 208, 469-478. doi: 10.1084/jem.20101876
8. Denkert, C., Loibl, S., Noske, A., Roller, M., Muller, B. M., Komor, M., et al. (2010). Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105-113. doi: 10.1200/JCO.2009.23.7370
9. Dunn, G. P., Old, L. J., and Schreiber, R. D. (2004). The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360. doi: 10.1146/annurev.immunol.22.012703.104803
10. Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff, J., et al. (2012). The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat. Rev. Gastroenterol. Hepatol. 9, 454-467.
11. Esposito, I., Kleeff, J., Bischoff, S. C., Fischer, L., Collecchi, P., Iorio, M., et al. (2002). The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab. Invest. 82, 1481-1492.
12. Esposito, I., Menicagli, M., Funel, N., Bergmann, F., Boggi, U., Mosca, F., et al. (2004). Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J. Clin. Pathol. 57, 630-636. doi: 10.1136/jcp.2003.014498
13. Evans, A., and Costello, E. (2012). The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front. Physiol. 3:270. doi: 10.3389/fphys.2012.00270
14. Fridman, W. H., Galon, J., Pages, F., Tartour, E., Sautes-Fridman, C., and Kroemer, G. (2011). Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 71, 5601-5605. doi: 10.1158/0008-5472.CAN-11-1316
15. Fridman, W. H., Pages, F., Sautes-Fridman, C., and Galon, J. (2012). The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306. doi: 10.1038/nrc3245
16. Fukunaga, A., Miyamoto, M., Cho, Y., Murakami, S., Kawarada, Y., Oshikiri, T., et al. (2004). CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28, e26-e31. doi: 10.1097/00006676-200401000-00023
17. Galli, S. J., Grimbaldeston, M., and Tsai, M. (2008). Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol. 8, 478-486. doi: 10.1038/nri2327
18. Galli, S. J., Nakae, S., and Tsai, M. (2005). Mast cells in the development of adaptive immune responses. Nat. Immunol. 6, 135-142. doi: 10.1038/ni1158
19. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964. doi: 10.1126/science.1129139
20. Galon, J., Pages, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., et al. (2012). Cancer classification using the Immunoscore: a worldwide task force. J. Transl. Med. 10, 205. doi: 10.1186/1479-5876-10-205
21. Gordon, S. (2003). Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23-35. doi: 10.1038/nri978
22. Hanahan, D., and Coussens, L. M. (2012). Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322. doi: 10.1016/j.ccr.2012.02.022
23. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. doi: 10.1016/j.cell.2011.02.013
24. Hidalgo, M. (2010). Pancreatic cancer. N. Engl. J. Med. 362, 1605-1617. doi: 10.1056/NEJMra0901557
25. Hiraoka, N., Onozato, K., Kosuge, T., and Hirohashi, S. (2006). Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12, 5423-5434. doi: 10.1158/1078-0432.CCR-06-0369
26. Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., et al. (2013). Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br. J. Cancer 108, 914-923. doi: 10.1038/bjc.2013.32
27. Kennedy, R., and Celis, E. (2008). Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev. 222, 129-144. doi: 10.1111/j.1600-065X.2008.00616.x
28. Khazaie, K., Blatner, N. R., Khan, M. W., Gounari, F., Gounaris, E., Dennis, K., et al. (2011). The significant role of mast cells in cancer. Cancer Metastasis Rev. 30, 45-60. doi: 10.1007/s10555-011-9286-z
29. Kleeff, J., Beckhove, P., Esposito, I., Herzig, S., Huber, P. E., Lohr, J. M., et al. (2007). Pancreatic cancer microenvironment. Int. J. Cancer 121, 699-705. doi: 10.1002/ijc.22871
30. Kurahara, H., Shinchi, H., Mataki, Y., Maemura, K., Noma, H., Kubo, F., et al. (2011). Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 167, e211-e219. doi: 10.1016/j.jss.2009.05.026.
31. Kurahara, H., Takao, S., Kuwahata, T., Nagai, T., Ding, Q., Maeda, K., et al. (2012). Clinical significance of folate receptor beta-expressing tumor-associated macrophages in pancreatic cancer. Ann. Surg. Oncol. 19, 2264-2271. doi: 10.1245/s10434-012-2263-0
32. Kurahara, H., Takao, S., Maemura, K., Mataki, Y., Kuwahata, T., Maeda, K., et al. (2013). M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer. Pancreas 42, 155-159. doi: 10.1097/MPA.0b013e318254f2d1
33. Laheru, D., and Jaffee, E. M. (2005). Immunotherapy for pancreatic cancer - science driving clinical progress. Nat. Rev. Cancer 5, 459-467. doi: 10.1038/nrc1630
34. Lewis, C. E., and Pollard, J. W. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66, 605-612. doi: 10.1158/0008-5472.CAN-05-4005
35. Mantovani, A., Sozzani, S., Locati, M., Allavena, P., and Sica, A. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549-555. doi: 10.1016/S1471-4906(02)02302-5
36. Mellman, I., Coukos, G., and Dranoff, G. (2011). Cancer immunotherapy comes of age. Nature 480, 480-489. doi: 10.1038/nature10673
37. Pages, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., et al. (2005). Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654-2666. doi: 10.1056/NEJMoa051424
38. Pedroza-Gonzalez, A., Xu, K., Wu, T. C., Aspord, C., Tindle, S., Marches, F., et al. (2011). Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J. Exp. Med. 208, 479-490. doi: 10.1084/jem.20102131
39. Puig-Kroger, A., Sierra-Filardi, E., Dominguez-Soto, A., Samaniego, R., Corcuera, M. T., Gomez-Aguado, F., et al. (2009). Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 69, 9395-9403. doi: 10.1158/0008-5472.CAN-09-2050
40. Qian, B. Z., and Pollard, J. W. (2010). Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51. doi: 10.1016/j.cell.2010.03.014
41. Ribatti, D., and Crivellato, E. (2012). Mast cells, angiogenesis, and tumour growth. Biochim. Biophys. Acta 1822, 2-8. doi: 10.1016/j.bbadis.2010.11.010
42. Ruffell, B., Affara, N. I., and Coussens, L. M. (2012). Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33, 119-126. doi: 10.1016/j.it.2011.12.001
43. Ruffell, B., Denardo, D. G., Affara, N. I., and Coussens, L. M. (2010). Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 21, 3-10. doi: 10.1016/j.cytogfr.2009.11.002
44. Ryschich, E., Notzel, T., Hinz, U., Autschbach, F., Ferguson, J., Simon, I., et al. (2005). Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin. Cancer Res. 11, 498-504.
45. Schreiber, R. D., Old, L. J., and Smyth, M. J. (2011). Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570. doi: 10.1126/science.1203486
46. Strouch, M. J., Cheon, E. C., Salabat, M. R., Krantz, S. B., Gounaris, E., Melstrom, L. G., et al. (2010). Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin. Cancer Res. 16, 2257-2265. doi: 10.1158/1078-0432.CCR-09-1230
47. Tassi, E., Gavazzi, F., Albarello, L., Senyukov, V., Longhi, R., Dellabona, P., et al. (2008). Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. J. Immunol. 181, 6595-6603.
48. Theoharides, T. C., and Conti, P. (2004). Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol. 25, 235-241. doi: 10.1016/j.it.2004.02.013
49. Theoharides, T. C., Kempuraj, D., Tagen, M., Conti, P., and Kalogeromitros, D. (2007). Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol. Rev. 217, 65-78. doi: 10.1111/j.1600-065X.2007.00519.x
50. Tjomsland, V., Niklasson, L., Sandstrom, P., Borch, K., Druid, H., Bratthall, C., et al. (2011). The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin. Dev. Immunol. 2011, 212810. doi: 10.1155/2011/212810
51. Von Bernstorff, W., Voss, M., Freichel, S., Schmid, A., Vogel, I., Johnk, C., et al. (2001). Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res. 7, 925S-932S.
52. Vonderheide, R. H., and Bayne, L. J. (2013). Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr. Opin. Immunol. 25, 200-205. doi: 10.1016/j.coi.2013.01.006
53. Wachsmann, M. B., Pop, L. M., and Vitetta, E. S. (2012). Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J. Investig. Med. 60, 643-663.
54. Wynn, T. A. (2004). Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4, 583-594. doi: 10.1038/nri1412
55. Zhu, J., Yamane, H., and Paul, W. E. (2010). Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 28, 445-489. doi: 10.1146/annurev-immunol-030409-101212
56. Zitvogel, L., Tesniere, A., and Kroemer, G. (2006). Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715-727. doi: 10.1038/nri1936